Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 4/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.34 |
| ▸ | LIPC | P11150 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834596 | 0.96 | ITGB1 (0.39) | MMP12ITGB1ITGA4ITGB7GPR132 | |
| SCHEMBL17834878 | 0.95 | ITGB1 (0.42) | MMP12ITGB1ITGA4ITGB7GPR132 | |
| SCHEMBL17834756 | 0.93 | F2 (0.36) | ITGB1ITGA4ITGB7PRSS1TMPRSS15 | |
| SCHEMBL17834927 | 0.93 | ST14 (0.37) | ITGB1PRSS1TMPRSS15KIFC1KLKB1 | |
| SCHEMBL17834633 | 0.93 | F2 (0.35) | PRSS1TMPRSS15KIFC1 | |
| SCHEMBL17834914 | 0.92 | F10 (0.37) | ITGB1PRSS1TMPRSS15 | |
| SCHEMBL17834924 | 0.92 | S1PR1 (0.36) | ITGB1ITGA4KIFC1 | |
| SCHEMBL17995211 | 0.92 | DPP4 (0.37) | ITGB1ITGA4ITGB7PRSS1TMPRSS15 | |
| SCHEMBL17834655 | 0.92 | PRSS1 (0.34) | ITGB1ITGA4ITGB7PRSS1TMPRSS15 | |
| SCHEMBL17834923 | 0.92 | ROCK2 (0.35) | ITGB1ITGA4KIFC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MMP12 4516/4885ITGB1 3589/4885ITGA4 4651/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MMP12 4516/4885ITGB1 3589/4885ITGA4 4651/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | MMP12 4447/4885ITGB1 3369/4885ITGA4 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.